百裕制药与诺华签订一款在研抗肿瘤小分子药物的独家许可协议

药渡 · 公众号 · 药品 · 2024-10-18 07:30

正文

2024年10月16日，百裕制药与诺华就一款小分子抗肿瘤药物签订独家许可协议。

根据协议，百裕将收到7000万美元首付款，以及可达11亿美元的开发、注册及商业化等各类里程碑付款和相应特许使用费。

诺华将获得该款小分子创新药的全球独家开发及商业化权利。

BFC Group在本次交易中担任百裕制药独家财务顾问。

这次战略合作是百裕向全球患者提供潜在抗肿瘤药物重要一步，期待积极成果实现。

关于百裕

百裕制药总部位于中国成都医学城，专注于药物发明发现，多次荣获国家奖项，专注银杏核心药效成分研究二十余年，成功开发现代植物药（银杏叶有效部位制剂）“银杏内酯注射液”及“银杏总内酯滴丸”。

Chengdu Baiyu enters into a license agreement for the development and commercialization of its Anti-tumor small molecule inhibitor

Baiyu to receive $70 million upfront, with potential for up to $1.1 billion in development, regulatory and commercial milestones as well as tiered royalties.

CHENGDU, Oct.16th, 2024-- Chengdu Baiyu Pharmaceutical Co., Ltd. ("Baiyu") today announced that it has entered into an exclusive license agreement with Novartis for a small molecule anti-tumor asset.

Under the terms of the license agreement, Baiyu will receive an upfront payment of $70 million and is eligible to receive additional development, regulatory and commercial milestones payments of up to $1.1 billion, as well as tiered royalties.

Novartis has been granted an exclusive worldwide license for the development and commercialization of this asset.

BFC Group acted as the exclusive financial advisor to Baiyu.

This collaboration is an important step for Baiyu in making potential anti-tumor drugs available to patients globally, and Baiyu look forward to positive results being realized.

About Chengdu Baiyu Biopharmaceutical Co., Ltd.

Founded in 2005, Baiyu is a pharmaceutical company headquartered in Chengdu, China. The company is dedicated to discover and develop innovative medicines, for which it has earned numerous prestigious national awards. With over 20 years of focused research on the core pharmacological components of Ginkgo biloba, we have successfully developed modern botanical drugs, including Ginkgolide Injection and Ginkgolide Dropping Pills.